After being first approved yesterday for a pill developed for COVID-19, Pfizer has announced the effectiveness rate of its self-developed pill. After Pfizer’s announcement, the shares of Merck & Co, which approved the pill yesterday, fell.
About 24 hours ago, the UK Pharmaceuticals and Healthcare Regulatory Board gave permission to use the COVID-19 pill Molnupiravir, developed by Merck & Co. had given. One day after taking a COVID-19 pill for the first time in the world, it is known for its coronavirus vaccine, which was developed jointly with BioNTech. from Pfizer An important announcement has come.
Prizer announced the effectiveness of the antiviral pill they developed for COVID-19. The company said the pill had hospitalizations and deaths from coronavirus. It blocked 89% announced. Thus, Pfizer signaled that Merck & Co, the first company to receive approval for the COVID-19 pill, will make a significant difference to its pill. Merck & Co announced last month that the pill reduced deaths and hospitalizations by 50%.
It is aimed to produce at least 50 million packages by the end of 2022:
The study, in which Pfizer shared this result, was performed on 1,219 COVID-19 patients. The test group in the study consisted of people diagnosed with mild to moderate COVID-19 and at least one serious risk, such as obesity and old age. The drug was administered after the onset of symptoms within the scope of the study. 3 and 5 days later given to the patients.
According to the results obtained, people who took the drug 3 days after the onset of symptoms 0.8% were hospitalized. It was determined that none of them died 28 days after the treatment. The hospitalization rate of patients in the placebo group was 7%, and 7 people died.
RELATED NEWS
Vaccine Opponents Announced They Will Form a Political Party Now
Similar results were seen in people who took the pill 5 days after the onset of symptoms. Patients taking the drug 1% hospitalized 6.7% of those in the placebo group were hospitalized. Ten people in the placebo group died. The company has not yet disclosed any side effects of the drug. However, he explained that 20% of the patients in both the treatment and placebo groups experienced adverse effects.
However, the company says it expects to produce 180,000 packs of the pill by the end of 2021, and by the end of 2022 this number will be higher. will reach at least 50 million explained. Following Pfizer’s announcement of the pill, the company’s shares rose 13%. Pfizer’s rival Merck & Co shares fell 6%.
Source :
https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-says-antiviral-pill-cuts-risk-severe-covid-19-by-89-2021-11-05/